In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding

Ann Intern Med. 2020 Aug 18;173(4):JC21. doi: 10.7326/ACPJ202008180-021.

Abstract

Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599-607. 32223112.

Publication types

  • Comment

MeSH terms

  • Anticoagulants / adverse effects
  • Dalteparin
  • Hemorrhage / chemically induced
  • Humans
  • Neoplasms* / complications
  • Pyrazoles
  • Pyridones
  • Recurrence
  • Venous Thromboembolism* / drug therapy
  • Venous Thromboembolism* / prevention & control

Substances

  • Anticoagulants
  • Pyrazoles
  • Pyridones
  • apixaban
  • Dalteparin